CC BY 4.0 · TH Open 2018; 02(02): e167-e172
DOI: 10.1055/s-0038-1645875
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Risk of Thrombosis in Patients Presenting with Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA)

Sivabaskari Pasupathy
1   Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia
2   Central Adelaide Local Health Network, Adelaide, South Australia, Australia
,
Susan Rodgers
3   Division of Hematology, SA Pathology, Adelaide, South Australia, Australia
4   School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia
,
Rosanna Tavella
1   Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia
2   Central Adelaide Local Health Network, Adelaide, South Australia, Australia
,
Simon McRae
2   Central Adelaide Local Health Network, Adelaide, South Australia, Australia
3   Division of Hematology, SA Pathology, Adelaide, South Australia, Australia
4   School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia
,
John F. Beltrame
1   Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia
2   Central Adelaide Local Health Network, Adelaide, South Australia, Australia
› Author Affiliations
Further Information

Publication History

02 January 2018

19 March 2018

Publication Date:
03 May 2018 (online)

Abstract

Patients presenting with myocardial infarction (MI) in the absence of obstructive coronary artery disease (CAD) is termed MI with nonobstructive coronary arteries (MINOCA). The underlying pathophysiology of MINOCA is multifactorial and in situ formation and subsequent spontaneous lysis of a coronary thrombus is often hypothesized as one of the mechanisms. The objective of this study is to determine whether MINOCA patients had a greater prothrombotic tendency in comparison to MI patients with obstructive CAD (MICAD). Prospectively, blood samples of 25 consecutive MINOCA patients (58 (interquartile range [IQR]: 48, 75) years, 48% women) and 25 age-/gender-matched MICAD patients (58 (IQR: 50, 66) years, 48% women) were obtained at 1 month after the initial presentation and overall thrombin generation potential and congenital/acquired thrombophilia states were assessed. As regard to results, overall thrombin generation parameters were similar (p > 0.05) between the MINOCA and MICAD groups, highlighting similar endogenous thrombin potential (1,590 nM/min; IQR: 1,380, 2,000 vs. 1,750 nM/min; IQR: 1,500, 2,040, respectively). There were no significant differences between MINOCA and MICAD, respectively, in respect to the numbers of patients with congenital thrombophilia states including factor V Leiden (0 vs. 4%) and prothrombin gene mutation (8 vs. 4%), decreased antithrombin (8 vs. 0%), protein C (0 vs. 0%), and protein S (4 vs. 0%). None of the patients demonstrated presence of lupus anticoagulant and anticardiolipin antibodies. Although MINOCA patients revealed thrombotic characteristics that are similar to those with MICAD, the results from this study are inconclusive and a larger study with healthy control subjects is required to assess the risk of thrombosis in MINOCA.

 
  • References

  • 1 Pasupathy S, Tavella R, Beltrame JF. The what, when, who, why, how and where of myocardial infarction with non-obstructive coronary arteries (MINOCA). Circ J 2016; 80 (01) 11-16
  • 2 Ibanez B, James S, Agewall S. , et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
  • 3 Kardasz I, De Caterina R. Myocardial infarction with normal coronary arteries: a conundrum with multiple aetiologies and variable prognosis: an update. J Intern Med 2007; 261 (04) 330-348
  • 4 Thygesen K, Alpert JS, Jaffe AS. , et al; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons; Biomarker Subcommittee; ECG Subcommittee; Imaging Subcommittee; Classification Subcommittee; Intervention Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; ESC Committee for Practice Guidelines (CPG); Document Reviewers. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60 (16) 1581-1598
  • 5 Rodgers SE, Wong A, Gopal RD, Dale BJ, Duncan EM, McRae SJ. Evaluation of pre-analytical variables in a commercial thrombin generation assay. Thromb Res 2014; 134 (01) 160-164
  • 6 Da Costa A, Tardy B, Haouchette K. , et al. Long term prognosis of patients with myocardial infarction and normal coronary angiography: impact of inherited coagulation disorders. Thromb Haemost 2004; 91 (02) 388-393
  • 7 Maiwald S, Oey RC, Sivapalaratnam S. , et al. Abnormal hemostatic parameters in patients with myocardial infarction but angiographically normal coronary arteries. Int J Cardiol 2014; 174 (03) 734-735
  • 8 Reynolds HR, Srichai MB, Iqbal SN. , et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation 2011; 124 (13) 1414-1425
  • 9 Rallidis LS, Belesi CI, Manioudaki HS. , et al. Myocardial infarction under the age of 36: prevalence of thrombophilic disorders. Thromb Haemost 2003; 90 (02) 272-278
  • 10 Dacosta A, Tardy-Poncet B, Isaaz K. , et al. Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries. Heart 1998; 80 (04) 338-340
  • 11 Da Costa A, Isaaz K, Faure E, Mourot S, Cerisier A, Lamaud M. Clinical characteristics, aetiological factors and long-term prognosis of myocardial infarction with an absolutely normal coronary angiogram; a 3-year follow-up study of 91 patients. Eur Heart J 2001; 22 (16) 1459-1465
  • 12 Van de Water NS, French JK, Lund M, Hyde TA, White HD, Browett PJ. Prevalence of factor V Leiden and prothrombin variant G20210A in patients age <50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol 2000; 36 (03) 717-722
  • 13 Mansourati J, Da Costa A, Munier S. , et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000; 83 (06) 822-825
  • 14 Rosendaal FR, Siscovick DS, Schwartz SM. , et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89 (08) 2817-2821
  • 15 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346 (8983): 1133-1134
  • 16 Vaarala O, Mänttäri M, Manninen V. , et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91 (01) 23-27
  • 17 Bili A, Moss AJ, Francis CW, Zareba W, Watelet LF, Sanz I. Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Thrombogenic Factors, and Recurrent Coronary Events Investigators. Circulation 2000; 102 (11) 1258-1263
  • 18 Segev A, Ellis MH, Segev F. , et al. High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors. Int J Cardiol 2005; 98 (03) 421-424
  • 19 Davies JO, Hunt BJ. Myocardial infarction in young patients without coronary atherosclerosis: assume primary antiphospholipid syndrome until proved otherwise. Int J Clin Pract 2007; 61 (03) 379-384
  • 20 Dacosta A, Guy JM, Rousset H. , et al. [Painless infarction in antiphospholipid syndrome]. Arch Mal Coeur Vaiss 1993; 86 (12) 1773-1775
  • 21 Bobrow RS. Excess factor VIII: a common cause of hypercoagulability. J Am Board Fam Pract 2005; 18 (02) 147-149
  • 22 Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21 (05) 731-738
  • 23 Gorog DA, Rakhit R, Parums D, Laffan M, Davies GJ. Raised factor VIII is associated with coronary thrombotic events. Heart 1998; 80 (04) 415-417
  • 24 Hernández V, Muñoz N, Montero MA, Camacho A, Lozano F, Fernández V. Acute myocardial infarction for thrombotic occlusion in patient with elevated coagulation factor VIII. Rev Esp Cardiol (Engl Ed) 2012; 65 (07) 673-674
  • 25 Kyrle PA, Minar E, Hirschl M. , et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343 (07) 457-462
  • 26 Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311 (08) 501-505
  • 27 Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation 2015; 131 (10) 861-870